Skip to content

Development Plan for Evorpacept

We are pursuing a robust development plan for evorpacept across a breadth of indications in solid and hematologic cancers with multiple combination partners.

Modality/
Target 		Program Indication
Phase
 Status
Evorpacept Programs
Anti-cancer Antibodies
ASPEN-06
Evorpacept, Herceptin®, CYRAMZA® + Paclitaxel¹
2L or 3L Advanced HER2-Overexpressing Gastric/Gastro­esophageal Junction (GEJ)
end of phase 2
Next steps pending FDA input
ASPEN-Breast
Evorpacept, Herceptin®+ chemotherapy
Enhertu®-Experienced HER2-Positive Breast Cancer
beginning of phase 2
Launching Q1 ‘25, FPI mid-year ’25
ASPEN-CRC
Evorpacept, Erbitux®+ chemotherapy
2L, EGFR-Naïve Metastatic Colorectal Cancer (CRC)
mid phase 1
Launching Q1 ‘25, FPI mid-year ’25
Zanidatamab¹ + Evorpacept
HER2-Expressing Breast Cancer and Other Cancers
end of phase 1
Data presented at SABCS ‘24
Sarclisa® + Dexamethasone² + Evorpacept
RRMM (Relapsed or Refractory Multiple Myeloma)
beginning of phase 1
FPI Q3 ‘24, Currently Enrolling
ADCs
ASPEN-07
Evorpacept + PADCEV®
Urothelial Cancer
mid/end of phase 1
Data update Q2’ 25
Enhertu® (I-SPY)³ + Evorpacept
HER2-Positive HER2-Low Metastatic Breast Cancer
mid/end of phase 1
Currently Enrolling
ALX2004 Program
ADC
Single-agent
dose-escalation and expansion
EFGR-Expressing Solid Tumors
beginning of phase 2
Filing IND Q1 '25

Evorpacept Programs

ASPEN-06
Evorpacept, Herceptin®, CYRAMZA® + Paclitaxel¹
Modality/Target
Anti-cancer Antibodies
Indication
2L or 3L Advanced HER2-Overexpressing Gastric/Gastro­esophageal Junction (GEJ)
Status
Next steps pending FDA input
end of phase 2
ASPEN-Breast
Evorpacept, Herceptin®+ chemotherapy
Modality/Target
Anti-cancer Antibodies
Indication
Enhertu®-Experienced HER2-Positive Breast Cancer
Status
Launching Q1 ‘25, FPI mid-year ’25
beginning of phase 2
ASPEN-CRC
Evorpacept, Erbitux®+ chemotherapy
Modality/Target
Anti-cancer Antibodies
Indication
2L, EGFR-Naïve Metastatic Colorectal Cancer (CRC)
Status
Launching Q1 ‘25, FPI mid-year ’25
mid phase 1
Zanidatamab¹ + Evorpacept
Modality/Target
Anti-cancer Antibodies
Indication
HER2-Expressing Breast Cancer and Other Cancers
Status
Data presented at SABCS ‘24
end of phase 1
Sarclisa® + Dexamethasone² + Evorpacept
Modality/Target
Anti-cancer Antibodies
Indication
RRMM (Relapsed or Refractory Multiple Myeloma)
Status
FPI Q3 ‘24, Currently Enrolling
beginning of phase 1
ASPEN-07
Evorpacept + PADCEV®
Modality/Target
ADCs
Indication
Urothelial Cancer
Status
Data update Q2’ 25
mid/end of phase 1
Enhertu® (I-SPY)³ + Evorpacept
Modality/Target
ADCs
Indication
HER2-Positive HER2-Low Metastatic Breast Cancer
Status
Currently Enrolling
mid/end of phase 1

ALX2004 Program

Single-agent
dose-escalation and expansion
Modality/Target
ADC
Indication
EFGR-Expressing Solid Tumors
Status
Filing IND Q1 '25
beginning of phase 2
Explore Our Clinical Trials

ALX-Sponsored Trial

ALX Oncology retains worldwide rights to evorpacept.

  1. Lilly supplies CYRAMZA® for ALX Oncology’s ASPEN-06 program
  2. Merck supplies KEYTRUDA® for ALX Oncology’s ASPEN-03 and ASPEN-04 programs